Print（PDF/123KB） Jun. 08, 2023 Corporate

Sumitomo Pharma Announces Changes in the Positions Assumed by Executive Officers and Other Key Positions

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) today announced the following changes in the positions assumed by Executive Officers and other key positions, effective July 1, 2023.

I. Changes in the Positions Assumed by Executive Officers (effective July 1, 2023)

Position as of July 1, 2023	Current position	Name
Executive Officer Drug Development Division Senior Vice President, Head of Drug Development Division CNS Strategic Alliance, Sumitomo Pharma America, Inc.	Executive Officer Drug Development Division Executive Director, Drug Development Division Executive Vice President and Chief Corporate Strategy Officer, Sunovion Pharmaceuticals Inc.	Yumi Sato
Executive Officer Chief Strategy Officer, Sumitomo Pharma America, Inc.	Executive Officer Executive Vice President, Sumitomo Pharma America Holdings, Inc.	Tsutomu Nakagawa

II. Changes in Personnel (effective July 1, 2023)

Corporate Departments

Position as of July 1, 2023	Current position	Name
Lead Senior Vice President, Sumitomo Pharma America, Inc.	Senior Oncology Strategy Officer, Sumitomo Pharma Oncology, Inc.	Masashi Murata
Vice President, Sumitomo Pharma America, Inc.	Senior Director, Special Missions for North America Business	Tatsuya Ito
Vice President, Sumitomo Pharma America, Inc.	Frontier Business Development Officer, Sumitomo Pharma America Holdings, Inc.	Tetsuya Uyama
Vice President, Sumitomo Pharma America, Inc.	Strategy Officer, Sunovion Pharmaceuticals Inc. (Sumitovant business)	Atsushi Kataoka